In fact, in the context of relapsed/refractory NHL, CD4:CD8 CAR-T cells showed comparable antitumor activity but reduced toxicity, especially severe CRS, compared with unselected commercial products.3 These positive results brought to the recent commercialization of the first CD4:CD8 CD19 CAR-T cell product (lisocabtagene maraleucel).3 26. This evidence concerns the gene CD19 and congenital rubella syndrome.